0001654954-24-006745.txt : 20240521
0001654954-24-006745.hdr.sgml : 20240521
20240521170141
ACCESSION NUMBER: 0001654954-24-006745
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240517
FILED AS OF DATE: 20240521
DATE AS OF CHANGE: 20240521
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rich Stuart
CENTRAL INDEX KEY: 0001841785
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34600
FILM NUMBER: 24970418
MAIL ADDRESS:
STREET 1: C/O TENAX THERAPEUTICS, INC.
STREET 2: ONE COPLEY PARKWAY, SUITE 490
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TENAX THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0000034956
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 262593535
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 101 GLEN LENNOX DRIVE
STREET 2: SUITE 300
CITY: CHAPEL HILL
STATE: NC
ZIP: 27517
BUSINESS PHONE: 919-855-2100
MAIL ADDRESS:
STREET 1: 101 GLEN LENNOX DRIVE
STREET 2: SUITE 300
CITY: CHAPEL HILL
STATE: NC
ZIP: 27517
FORMER COMPANY:
FORMER CONFORMED NAME: OXYGEN BIOTHERAPEUTICS, INC.
DATE OF NAME CHANGE: 20080703
FORMER COMPANY:
FORMER CONFORMED NAME: SYNTHETIC BLOOD INTERNATIONAL INC
DATE OF NAME CHANGE: 19920703
FORMER COMPANY:
FORMER CONFORMED NAME: SINEQUANON CORP
DATE OF NAME CHANGE: 19901219
4
1
section16.xml
PRIMARY DOCUMENT
X0508
4
2024-05-17
0000034956
TENAX THERAPEUTICS, INC.
TENX
0001841785
Rich Stuart
101 GLEN LENNOX DRIVE. SUITE 300
CHAPEL HILL
NC
27517
true
true
false
Chief Medical Officer
false
Common Stock
266
D
Common Stock
1194
I
By Stuart Rich 2022 Irrevocable Trust
Common Stock
1194
I
By Andrea Rich 2021 Irrevocable Trus
Stock Option (right to buy)
3.549
2024-05-17
4
A
false
119
0.00
A
2034-05-17
Common Stock
119
119
D
Stock Option (right to buy)
2848
2031-01-15
Common Stock
157
157
D
Stock Option (right to buy)
992
2032-06-09
Common Stock
63
63
D
These shares were previously reported as 424,347 but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
These shares were previously reported as 1,909,585, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
The Reporting Person is special asset advisor to the Stuart Rich 2022 Irrevocable Trust, a Spousal Lifetime Access Trust (the "Trust"). As such, the Reporting Person has voting and dispositive power over the reported securities held in the Trust, however disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
The Reporting Person is co-trustee of the Andrea Rich 2021 Irrevocable Trust and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027 and May 17, 2028, subject to the Reporting Person's continued employment.
These options were previously reported as covering 250,000 shares at an exercise price of $1.78 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
The options vest and become exercisable in four equal installments, with 25% vesting after the start of a Phase 3 clinical trial, 25% vesting after the database lock with respect to the trial, 25% vesting after the opening of an Investigational New Drug Application with the U.S. Food and Drug Administration ("FDA"), and 25% vesting after the approval from the FDA, subject to the Reporting Person's continued employment.
These options were previously reported as covering 100,000 shares at an exercise price of $0.62 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
/s/ S. Halle Vakani, as Attorney-in-Fact
2024-05-21